Unmet Needs in Managing Myocardial Infarction in Patients With Malignancy
Patients with cancer face a high short-term risk of arterial thromboembolism. One of the most fatal manifestations of arterial thromboembolism is myocardial infarction (MI), and patients with cancer face a 3-fold greater risk of MI than patients without cancer. The individual risk for arterial throm...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-05-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fcvm.2019.00057/full |
| _version_ | 1828764380443967488 |
|---|---|
| author | Taku Inohara Taku Inohara Ayaka Endo Ayaka Endo Chiara Melloni |
| author_facet | Taku Inohara Taku Inohara Ayaka Endo Ayaka Endo Chiara Melloni |
| author_sort | Taku Inohara |
| collection | DOAJ |
| description | Patients with cancer face a high short-term risk of arterial thromboembolism. One of the most fatal manifestations of arterial thromboembolism is myocardial infarction (MI), and patients with cancer face a 3-fold greater risk of MI than patients without cancer. The individual risk for arterial thrombotic events in patients with cancer is determined by the complex interaction of baseline cardiovascular risk factors, cancer type and stage, chemotherapeutic regimen, and other general contributing factors for thrombosis. Managing MI in patients with cancer is a clinical challenge, particularly due to cancer's unique pathophysiology, which makes it difficult to balance thrombotic and bleeding risks in this specific patient population. When patients with cancer present with MI, a limited proportion are treated with guideline-recommended therapy, such as antiplatelet therapy or invasive revascularization. Despite the limited evidence, existing reports consistently suggest similar clinical benefits of guideline-recommended therapy when administered to patients with cancer presenting with MI. In this review, we briefly summarize the available evidence, clinical challenges, and future perspectives on simultaneous management of MI and cancer, with a focus on invasive strategy. |
| first_indexed | 2024-12-11T02:20:48Z |
| format | Article |
| id | doaj.art-31a8b3ac8feb4952a1d22c8e8c4c1610 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-11T02:20:48Z |
| publishDate | 2019-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-31a8b3ac8feb4952a1d22c8e8c4c16102022-12-22T01:24:04ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2019-05-01610.3389/fcvm.2019.00057440112Unmet Needs in Managing Myocardial Infarction in Patients With MalignancyTaku Inohara0Taku Inohara1Ayaka Endo2Ayaka Endo3Chiara Melloni4Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, United StatesDepartment of Cardiology, Keio University School of Medicine, Tokyo, JapanDepartment of Cardiology, Keio University School of Medicine, Tokyo, JapanDepartment of Cardiology, Saiseikai Central Hospital, Tokyo, JapanDuke Clinical Research Institute, Duke University Medical Center, Durham, NC, United StatesPatients with cancer face a high short-term risk of arterial thromboembolism. One of the most fatal manifestations of arterial thromboembolism is myocardial infarction (MI), and patients with cancer face a 3-fold greater risk of MI than patients without cancer. The individual risk for arterial thrombotic events in patients with cancer is determined by the complex interaction of baseline cardiovascular risk factors, cancer type and stage, chemotherapeutic regimen, and other general contributing factors for thrombosis. Managing MI in patients with cancer is a clinical challenge, particularly due to cancer's unique pathophysiology, which makes it difficult to balance thrombotic and bleeding risks in this specific patient population. When patients with cancer present with MI, a limited proportion are treated with guideline-recommended therapy, such as antiplatelet therapy or invasive revascularization. Despite the limited evidence, existing reports consistently suggest similar clinical benefits of guideline-recommended therapy when administered to patients with cancer presenting with MI. In this review, we briefly summarize the available evidence, clinical challenges, and future perspectives on simultaneous management of MI and cancer, with a focus on invasive strategy.https://www.frontiersin.org/article/10.3389/fcvm.2019.00057/fullmyocardial infarctioncancerarterial thrombosischemotherapyinvasive strategy |
| spellingShingle | Taku Inohara Taku Inohara Ayaka Endo Ayaka Endo Chiara Melloni Unmet Needs in Managing Myocardial Infarction in Patients With Malignancy Frontiers in Cardiovascular Medicine myocardial infarction cancer arterial thrombosis chemotherapy invasive strategy |
| title | Unmet Needs in Managing Myocardial Infarction in Patients With Malignancy |
| title_full | Unmet Needs in Managing Myocardial Infarction in Patients With Malignancy |
| title_fullStr | Unmet Needs in Managing Myocardial Infarction in Patients With Malignancy |
| title_full_unstemmed | Unmet Needs in Managing Myocardial Infarction in Patients With Malignancy |
| title_short | Unmet Needs in Managing Myocardial Infarction in Patients With Malignancy |
| title_sort | unmet needs in managing myocardial infarction in patients with malignancy |
| topic | myocardial infarction cancer arterial thrombosis chemotherapy invasive strategy |
| url | https://www.frontiersin.org/article/10.3389/fcvm.2019.00057/full |
| work_keys_str_mv | AT takuinohara unmetneedsinmanagingmyocardialinfarctioninpatientswithmalignancy AT takuinohara unmetneedsinmanagingmyocardialinfarctioninpatientswithmalignancy AT ayakaendo unmetneedsinmanagingmyocardialinfarctioninpatientswithmalignancy AT ayakaendo unmetneedsinmanagingmyocardialinfarctioninpatientswithmalignancy AT chiaramelloni unmetneedsinmanagingmyocardialinfarctioninpatientswithmalignancy |